StockWatch
·

Panorama Studios International Ltd Q1 FY27 Results

PANORAMAQ1 FY27 Results
Filing
Result:Good· Market: FlatBroad basedMargin expansionBase effect
MetricValueQ4 FY26Q1 FY26
Revenue183.07 Cr182.4%34.3%
Total Income185.16 Cr172.5%34.3%
Expenditure168.23 Cr199.9%26.4%
PBT16.93 Cr42.9%253.2%
Net Profit12.71 Cr77.5%263.0%
OPM10.94%8.99pp5.38pp
NPM6.87%3.67pp4.33pp
EPS0.5252.9%27.8%
View full financials

Revenue and adjusted PAT both grew strongly YoY with genuine operating-margin expansion (5.56%→10.94%) rather than a one-off, but the near-tripling of profit is flattered by a modest year-ago base, keeping it just below very_good.

Q1 FY-2027 RESULTS · PANORAMA

Panorama Studios Q1 FY27: consol PAT up 263% YoY on 34% revenue growth, margins expand

PAT +262.96% YoY · revenue +34.27% · margins expanding

14 Aug 2026 · 3 min read
Revenue

₹183.07 Cr

+34.27% YoY

PAT (consolidated)

₹12.71 Cr

+262.96% YoY

Net margin

6.87%

+4.3pp YoY

EPS

₹0.52

Panorama Studios International's consolidated Q1 FY27 (quarter ended June 30, 2026) revenue from operations rose 34.3% YoY to ₹183.07 Cr from ₹136.35 Cr, while consolidated profit for the period more than tripled YoY to ₹12.71 Cr from ₹3.50 Cr — a 262.96% jump, though off a modest year-ago base. Operating margin (EBITDA/revenue) expanded to 10.94% from 5.56% YoY, and net margin expanded to 6.87% from 2.54% YoY, indicating topline growth converted disproportionately to profit as operating costs grew slower than revenue.

The scoreboard

Q1 FY-2027 vs prior quarters

Consolidated P&L, ₹ Crore
Q1 FY-2027QoQYoY
Revenue₹183.07 Cr+182.4%+34.3%
Expenses₹168.23 Cr+199.9%+26.4%
PAT₹12.71 Cr+77.54%+262.96%
Net margin6.87%-3.7pp+4.3pp
EPS₹0.52+52.9%-27.8%

Sequentially, revenue jumped from ₹64.83 Cr in Q4 FY26 (+182.4% QoQ), but margins compressed versus that quarter (OPM 19.93%→10.94%, NPM 10.54%→6.87%). Q4 FY26 was a lower-revenue but richer-margin quarter — consistent with the project/release-driven revenue recognition typical of film production and distribution — so the QoQ swing reflects business mix rather than deterioration; the YoY comparison is the more reliable read on trend.

34.6939.8845.0850.2755.4647.505-1106-0406-3007-2308-14Q1 FY-2027 results
The tape into the print — daily closes, last 3 months

The stock went into the print at ₹47.5, down 4.8% over the past month of trading.

₹ Cr
-5.428.0221.4734.9231.02Q4 FY25rev ₹213 Cr3.5Q1 FY26rev ₹136 Cr0.84Q2 FY26rev ₹78 Cr-1.52Q3 FY26rev ₹29 Cr7.16Q4 FY26rev ₹65 Cr12.71Q1 FY27rev ₹183 Cr
Quarterly consolidated PAT, ₹ Crore

For context: this is the second-highest quarterly PAT of the last 6 quarters; PAT has now risen for 2 consecutive quarters.

Beyond the headline

What the summary numbers don't show

EPS: ₹0.52 consolidated basic (₹0.56 standalone) vs ₹0.21 consolidated a year ago; prior-period EPS recalculated for the 2:5 bonus issue done December 2, 2025

There is no formal management guidance or prior concall commentary on record for this company, and a web search turned up no brokerage previews or consensus estimates for this quarter — both the guidance and Street-expectation checks return unknown, consistent with a small-cap that has limited analyst coverage. The quarter's corporate activity — new distribution/exhibition deals for the Telugu film 'Hrudayam', the Malayalam film 'Paisawala', 'Toxic' (Kerala exhibition), 'Kanimangalam Kovilakam' film rights and airborne rights for 'Faces', alongside a board-approved 10% stake investment in Rhea & Dia Enterprises announced August 13, 2026 — points to an active content pipeline aligned with the reported scale-up in the production/distribution vertical, though the filing carries no management press release quantifying these deals' contribution.

  • W1

    Whether OPM holds above the 10.94% Q1 FY27 level or reverts toward the 19.93% seen in Q4 FY26 as project mix shifts

  • W2

    Revenue contribution in coming quarters from the deals signed this quarter (Hrudayam, Toxic, Kanimangalam Kovilakam, Faces, Paisawala)

  • W3

    Returns/utilization from the newly announced 10% stake in Rhea & Dia Enterprises

Informational and educational content only. Not investment advice.